Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Dementia Associated With Alzheimer's Disease Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Dementia Associated With Alzheimer's Disease Overview | 8 | 1 |
| Pipeline Products for Dementia Associated With Alzheimer's Disease Comparative Analysis | 9 | 1 |
| Dementia Associated With Alzheimer's Disease Therapeutics under Development by Companies | 10 | 1 |
| Dementia Associated With Alzheimer's Disease Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Dementia Associated With Alzheimer's Disease Pipeline Products Glance | 12 | 3 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Unknown Stage Products | 14 | 1 |
| Dementia Associated With Alzheimer's Disease Products under Development by Companies | 15 | 1 |
| Dementia Associated With Alzheimer's Disease Products under Investigation by Universities/Institutes | 16 | 1 |
| Dementia Associated With Alzheimer's Disease Companies Involved in Therapeutics Development | 17 | 8 |
| Adamas Pharmaceuticals, Inc. | 17 | 1 |
| AgeneBio Inc. | 18 | 1 |
| Amarantus Bioscience Holdings, Inc. | 19 | 1 |
| Boehringer Ingelheim GmbH | 20 | 1 |
| Chase Pharmaceuticals Corporation | 21 | 1 |
| Eisai Co., Ltd. | 22 | 1 |
| H. Lundbeck A/S | 23 | 1 |
| MediPost Co., Ltd. | 24 | 1 |
| Dementia Associated With Alzheimer's Disease Therapeutics Assessment | 25 | 10 |
| Assessment by Monotherapy Products | 25 | 1 |
| Assessment by Combination Products | 26 | 1 |
| Assessment by Target | 27 | 2 |
| Assessment by Mechanism of Action | 29 | 2 |
| Assessment by Route of Administration | 31 | 2 |
| Assessment by Molecule Type | 33 | 2 |
| Drug Profiles | 35 | 24 |
| (donepezil hydrochloride + memantine hydrochloride ER) Drug Profile | 35 | 2 |
| (donepezil hydrochloride + solifenacin succinate) Drug Profile | 37 | 2 |
| BI-409306 Drug Profile | 39 | 2 |
| E-2609 Drug Profile | 41 | 3 |
| eltoprazine Drug Profile | 44 | 5 |
| Gln-1062 Drug Profile | 49 | 3 |
| levetiracetam Drug Profile | 52 | 2 |
| LUAF-20513 Drug Profile | 54 | 1 |
| Neurostem Drug Profile | 55 | 2 |
| salicylamine Drug Profile | 57 | 1 |
| TAK-070 Drug Profile | 58 | 1 |
| Dementia Associated With Alzheimer's Disease Dormant Projects | 59 | 1 |
| Dementia Associated With Alzheimer's Disease Discontinued Products | 60 | 1 |
| Dementia Associated With Alzheimer's Disease Product Development Milestones | 61 | 11 |
| Featured News &Press Releases | 61 | 1 |
| Aug 31, 2016: Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC Patent Litigation | 61 | 1 |
| Jul 27, 2016: Chase Pharmaceuticals Presents Phase 2 Results for CPC-201 at 2016 Alzheimer s Association International Conference | 61 | 2 |
| Feb 17, 2016: AgeneBio to Present at Neuroscience BioPartnering &Investment Forum | 63 | 1 |
| Dec 15, 2015: AgeneBio Launches New HOPE4MCI Phase 3 Clinical Trial Website | 63 | 1 |
| Dec 08, 2015: Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression | 64 | 2 |
| Nov 24, 2015: AgeneBio to Present at Future of Innovation in Medicine Conference | 66 | 1 |
| Oct 22, 2015: AgeneBio to Present at 8th Annual Clinical Trials on Alzheimer s Disease | 67 | 1 |
| Sep 15, 2015: NIH Awards $7.5 Million Grant for AgeneBio HOPE4MCI Phase 3 Clinical Trial to Delay the Onset of Alzheimer's Dementia | 67 | 1 |
| Mar 11, 2015: AgeneBio Announces Publication of Phase 2 Clinical Trial Results for New Approach to Delaying the Onset of Alzheimer s Dementia | 68 | 1 |
| Jan 28, 2015: AgeneBio Receives Grant from Alzheimer s Drug Discovery Foundation for New Approach to Delaying the Onset of Alzheimer s Dementia | 69 | 1 |
| May 20, 2014: Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories | 70 | 1 |
| May 15, 2012: Adamas Announces Successful End-Of-Phase II Meeting With FDA For Arimenda | 70 | 2 |
| Appendix | 72 | 2 |
| Methodology | 72 | 1 |
| Coverage | 72 | 1 |
| Secondary Research | 72 | 1 |
| Primary Research | 72 | 1 |
| Expert Panel Validation | 72 | 1 |
| Contact Us | 72 | 1 |
| Disclaimer | 73 | 1 |